Evidence map›Paper›PMID 29250485›Full record

ArticleFrontiers in oncology2017

Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from

Deborah K Hill, Andreas Heindl, Konstantinos Zormpas-Petridis, David J Collins, Leslie R Euceda, Daniel N Rodrigues, Siver A Moestue, Yann Jamin, Dow-Mu Koh, Yinyin Yuan and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Artificial intelligence at the intersection of pathology and radiology in prostate cancer.Diagnostic and interventional radiology (Ankara, Turkey) · 2019
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Deborah K HillDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Andreas HeindlDivision of Molecular Pathology, Centre for Evolution and Cancer, Centre for Molecular Pathology, The Institute of Cancer Research, London, United Kingdom.
Konstantinos Zormpas-PetridisCRUK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom.
David J CollinsCRUK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom.
Leslie R EucedaDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Daniel N RodriguesProstate Cancer Targeted Therapy Group, Drug Development Unit, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom.
Siver A MoestueDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Yann JaminCRUK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom.
Dow-Mu KohCRUK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom.
Yinyin YuanDivision of Molecular Pathology, Centre for Evolution and Cancer, Centre for Molecular Pathology, The Institute of Cancer Research, London, United Kingdom.
Tone F BathenDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Martin O LeachCRUK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom.
Matthew D BlackledgeCRUK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom.
Institute of Cancer Research · GBNorwegian University of Science and Technology · NONord University · NORoyal Marsden NHS Foundation Trust · GBSt Olav's University Hospital · NO

Funding

Cancer Research UK 16464Wellcome Trust
6 · The paper itself

Abstract

Diffusion-weighted magnetic resonance imaging (DWI) enables non-invasive, quantitative staging of prostate cancer via measurement of the apparent diffusion coefficient (ADC) of water within tissues. In cancer, more advanced disease is often characterized by higher cellular density (cellularity), which is generally accepted to correspond to a lower measured ADC. A quantitative relationship between tissue structure and

Indexed as

cellularitydiffusion-weighted imagingmouse models of cancerprostate cancerwhole-slide histology

Identifiers

PMID29250485
PMCPMC5717839
OpenAlexW2775488558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.